NLRP3, NLRP1, NLRC4, and AIM2 inflammasome inhibitors should be considered in SLE patients who show disordered Th1/Tfh or Th17/Treg profiles; the NLRP3 inhibitors may be helpful for patients with dendritic cell disorders (22). This evidence concerns the gene NLRC4 and systemic lupus erythematosus.